Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Cibus
CBUS
Cibus
Population Growth And Climate Trends Will Drive Gene-edited Crop Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
14 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$25.00
95.0% undervalued
intrinsic discount
21 Aug
US$1.25
Loading
1Y
-82.5%
7D
-15.0%
Author's Valuation
US$25.0
95.0% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$25.0
95.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
308m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$307.9m
Earnings US$28.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
62.58%
Biotech revenue growth rate
11.73%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.30%
Calculation
US$28.69m
Earnings '28
x
141.30x
PE Ratio '28
=
US$4.05b
Market Cap '28
US$4.05b
Market Cap '28
/
115.43m
No. shares '28
=
US$35.12
Share Price '28
US$35.12
Share Price '28
Discounted to 2025 @ 11.99% p.a.
=
US$25.00
Fair Value '25